SAN DIEGO--(BUSINESS WIRE)--Cytori (NASDAQ: CYTX) announced publication of the first preclinical study to demonstrate adipose-derived stem and regenerative cells (ADRCs) significantly improved cardiac function after a heart attack. This preclinical cardiac cell therapy study was reported online ahead of print in the International Journal of Cardiology. The study was funded by Cytori Therapeutics and conducted at Tulane University.
